相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
Byoung Soo Kwon et al.
THORACIC CANCER (2020)
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
Kirstin Perdrizet et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases
Kai Yin et al.
LUNG CANCER (2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
Lizza E. L. Hendriks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis
Weiwei Yan et al.
RADIATION ONCOLOGY (2019)
A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
Zhenyu Pan et al.
FRONTIERS IN ONCOLOGY (2019)
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
Tao Jiang et al.
EUROPEAN JOURNAL OF CANCER (2019)
Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
Xueyang Hu et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer
Miyuki Abe et al.
INTERNATIONAL CANCER CONFERENCE JOURNAL (2019)
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng et al.
LANCET ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
Maximilian Hochmair
TARGETED ONCOLOGY (2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Thanyanan Reungwetwattana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
Karima Saboundji et al.
TARGETED ONCOLOGY (2018)
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
Shigeki Nanjo et al.
BRITISH JOURNAL OF CANCER (2018)
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Chinami Masuda et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient
Maria Gion et al.
LUNG CANCER (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2017)
Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
J. Remon et al.
CANCER TREATMENT REVIEWS (2017)
Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain
Mayur M. Patel et al.
CNS DRUGS (2017)
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
Shigeki Nanjo et al.
ONCOTARGET (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Elizabeth Dudnik et al.
LUNG CANCER (2016)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
Bin-Chi Liao et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
Justine L. Kuiper et al.
LUNG CANCER (2015)
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
Toshihiko Iuchi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors
Su Jin Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Leptomeningeal metastases in the MRI era
J. L. Clarke et al.
NEUROLOGY (2010)
Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier
David S. Miller
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
The role of the EGFR signaling in tumor microenvironment
Antonella De Luca et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents
Josep Tabernero
MOLECULAR CANCER RESEARCH (2007)
Angiostatin prolongs the survival of mice with leptomeningeal metastases
JC Reijneveld et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
分享论文
